Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Chief Business Officer | January 02, 2026 | January 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date January 02, 2026 · Filed January 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,095 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Sale · Disposed 1,879 · Balance 83,095 F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 3, 2026 02:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 1,879 | $13.73 | $25,798.67 |
DisclosureSEC source: 0001864159-26-000002 · form4-01022026_090112.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,095 F1 · kind: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $10.59 | $0.00 |
DisclosureSEC source: 0001864159-25-000006 · form4-12032025_081207.xml · derivative · entry 4 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,768 Underlying: Common Stock · 3,333 shares Expires 2031-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 633 | $33.52 | $21,221.14 |
DisclosureSEC source: 0001864159-25-000006 · form4-12032025_081207.xml · nonDerivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,974 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F3 · price: The weighted average sale price for the transaction reported was $33.5247 and the range of prices were between $33.28 and $33.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,700 | $32.85 | $88,707.96 |
DisclosureSEC source: 0001864159-25-000006 · form4-12032025_081207.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,607 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F2 · price: The weighted average sale price for the transaction reported was $32.8548 and the range of prices were between $32.27 and $33.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 3,333 | $10.59 | $35,296.47 |
DisclosureSEC source: 0001864159-25-000006 · form4-12032025_081207.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $10.59 | $0.00 |
DisclosureSEC source: 0001864159-25-000005 · form4-11142025_081103.xml · derivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,101 Underlying: Common Stock · 3,333 shares Expires 2031-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 3,333 | $30.00 | $99,990.00 |
DisclosureSEC source: 0001864159-25-000005 · form4-11142025_081103.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,974 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 3,333 | $10.59 | $35,296.47 |
DisclosureSEC source: 0001864159-25-000005 · form4-11142025_081103.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2024 and 2,834 shares acquired under the Plan on May 15, 2025. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 6,666 | $0.00 Strike: $10.59 | $0.00 |
DisclosureSEC source: 0001864159-25-000003 · form4-10302025_081001.xml · derivative · entry 5 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,434 Underlying: Common Stock · 6,666 shares Expires 2031-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 9,999 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001864159-25-000003 · form4-10302025_081001.xml · derivative · entry 4 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,333 Underlying: Common Stock · 9,999 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 16,665 | $30.06 | $500,986.56 |
DisclosureSEC source: 0001864159-25-000003 · form4-10302025_081001.xml · nonDerivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,139 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F2 · price: The weighted average sale price for the transaction reported was $30.0622 and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 6,666 | $10.59 | $70,592.94 |
DisclosureSEC source: 0001864159-25-000003 · form4-10302025_081001.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 9,999 | $4.21 | $42,095.79 |
DisclosureSEC source: 0001864159-25-000003 · form4-10302025_081001.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 3, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001415889-25-011874 · form4-05022025_080503.xml · derivative · entry 4 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,332 Underlying: Common Stock · 3,333 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 01, 2025 Filed May 3, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 400 | $32.60 | $13,041.36 |
DisclosureSEC source: 0001415889-25-011874 · form4-05022025_080503.xml · nonDerivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,139 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F3 · price: The weighted average sale price for the transaction reported was $32.6034 and the range of prices were between $32.52 and $33.66. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 01, 2025 Filed May 3, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,933 | $31.95 | $93,703.19 |
DisclosureSEC source: 0001415889-25-011874 · form4-05022025_080503.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,539 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F2 · price: The weighted average sale price for the transaction reported was $31.9479 and the range of prices were between $31.44 and $32.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 01, 2025 Filed May 3, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 3,333 | $4.21 | $14,031.93 |
DisclosureSEC source: 0001415889-25-011874 · form4-05022025_080503.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2025 Filed Apr 24, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 3,334 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001415889-25-011243 · form4-04232025_080401.xml · derivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,665 Underlying: Common Stock · 3,334 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 21, 2025 Filed Apr 24, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 3,334 | $30.00 | $100,020.00 |
DisclosureSEC source: 0001415889-25-011243 · form4-04232025_080401.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,139 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. Read SEC document |
| April 21, 2025 Filed Apr 24, 2025 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 3,334 | $4.21 | $14,036.14 |
DisclosureSEC source: 0001415889-25-011243 · form4-04232025_080401.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 3,334 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001415889-25-007104 · form4-03052025_080309.xml · derivative · entry 4 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,999 Underlying: Common Stock · 3,334 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 901 | $32.85 | $29,598.66 |
DisclosureSEC source: 0001415889-25-007104 · form4-03052025_080309.xml · nonDerivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,139 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F3 · price: The weighted average sale price for the transaction reported was $32.8509 and the range of prices were between $32.53 and $33.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,433 | $31.88 | $77,575.72 |
DisclosureSEC source: 0001415889-25-007104 · form4-03052025_080309.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,040 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F2 · price: The weighted average sale price for the transaction reported was $31.8848 and the range of prices were between $31.50 and $32.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 3,334 | $4.21 | $14,036.14 |
DisclosureSEC source: 0001415889-25-007104 · form4-03052025_080309.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 3,334 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001415889-25-003165 · form4-02052025_080201.xml · derivative · entry 5 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,333 Underlying: Common Stock · 3,334 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 100 | $43.60 | $4,360.00 |
DisclosureSEC source: 0001415889-25-003165 · form4-02052025_080201.xml · nonDerivative · entry 4 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,139 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 816 | $42.77 | $34,900.56 |
DisclosureSEC source: 0001415889-25-003165 · form4-02052025_080201.xml · nonDerivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,239 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F3 · price: The weighted average sale price for the transaction reported was $42.7703 and the range of prices were between $42.56 and $43.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,418 | $42.08 | $101,738.80 |
DisclosureSEC source: 0001415889-25-003165 · form4-02052025_080201.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,055 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F2 · price: The weighted average sale price for the transaction reported was $42.0756 and the range of prices were between $41.55 and $42.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 01:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 3,334 | $4.21 | $14,036.14 |
DisclosureSEC source: 0001415889-25-003165 · form4-02052025_080201.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 63,000 | $0.00 Strike: $53.24 | $0.00 |
DisclosureSEC source: 0001415889-25-000554 · form4-01032025_050101.xml · derivative · entry 7 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2035-01-01 F8 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 200 | $57.37 | $11,473.00 |
DisclosureSEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 6 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,139 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F7 · price: The weighted average sale price for the transaction reported was $57.365 and the range of prices were between $57.35 and $57.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 1,000 | $56.78 | $56,777.80 |
DisclosureSEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 5 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,339 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F6 · price: The weighted average sale price for the transaction reported was $56.7778 and the range of prices were between $56.33 and $57.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 3,444 | $55.76 | $192,032.96 |
DisclosureSEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 4 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,339 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F5 · price: The weighted average sale price for the transaction reported was $55.7587 and the range of prices were between $55.24 and $56.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 5,768 | $54.51 | $314,420.02 |
DisclosureSEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,783 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F4 · price: The weighted average sale price for the transaction reported was $54.5111 and the range of prices were between $54.21 and $55.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,922 | $53.76 | $157,081.46 |
DisclosureSEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,551 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. F3 · price: The weighted average sale price for the transaction reported was $53.7582 and the range of prices were between $53.20 and $54.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,473 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 23:25 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 1 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001415889-24-029989 · form4-12202024_111213.xml · derivative · entry 4 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,999 Underlying: Common Stock · 1 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 1, 2024 and the balance vests in equal monthly installments thereafter over a three year period. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 23:25 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 9,880 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001415889-24-029989 · form4-12202024_111213.xml · derivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,870 Underlying: Common Stock · 9,880 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on January 1, 2023 and the balance vests in equal monthly installments thereafter over a three year period. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 23:25 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 1 | $14.02 | $14.02 |
DisclosureSEC source: 0001415889-24-029989 · form4-12202024_111213.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 23:25 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 9,880 | $20.24 | $199,971.20 |
DisclosureSEC source: 0001415889-24-029989 · form4-12202024_111213.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:32 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001415889-24-024078 · form4-09272024_110955.xml · derivative · entry 3 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,667 Underlying: Common Stock · 50,000 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:32 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 50,000 | $45.96 | $2,297,755.00 |
DisclosureSEC source: 0001415889-24-024078 · form4-09272024_110955.xml · nonDerivative · entry 2 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,592 F2 · price: The weighted average sale price for the transaction reported was $45.9551 and the range of prices were between $45.55 and $46.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 23:32 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 50,000 | $4.21 | $210,500.00 |
DisclosureSEC source: 0001415889-24-024078 · form4-09272024_110955.xml · nonDerivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,189 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,752 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023 and 2,834 shares acquired under the Plan on May 15, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:50 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-24-000433 · doc4.xml · derivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:33 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-23-001878 · doc4.xml · derivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:26 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 106,750 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001209191-22-001827 · doc4.xml · derivative · entry 1 Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,750 Underlying: Common Stock · 106,750 shares Expires 2032-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.